Koyfin Home > Directory > Health Care > Gilead Sciences Inc > Repurchase of Common Stock

Gilead Sciences Inc Repurchase of Common Stock Chart (GILD)

Gilead Sciences Inc annual/quarterly Repurchase of Common Stock from 2010 to 2020.
  • Gilead Sciences Inc Repurchase of Common Stock for the quarter ending September 09, 2020 was $-201m a 47.76% decrease of -96m year over year
  • Gilead Sciences Inc Repurchase of Common Stock for the last 12 months ending September 09, 2020 was $-1,688m a -3.61% increase of 61m year over year
  • Gilead Sciences Inc Annual Repurchase of Common Stock for 2019 was $-1,749m a -65.81% increase of 1,151m from 2018
  • Gilead Sciences Inc Annual Repurchase of Common Stock for 2018 was $-2,900m a 67.10% decrease of -1,946m from 2017
  • Gilead Sciences Inc Annual Repurchase of Common Stock for 2017 was $-954m a -1,053.14% increase of 10,047m from 2016
Other Cash Flow Metrics:
  • Gilead Sciences Inc Cash Flow from Operations for the quarter ending September 09, 2018 was $2,212m a -24.46% decrease of -541m year over year
  • Gilead Sciences Inc Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $1,592m a -123.19% decrease of -1,962m year over year
  • Gilead Sciences Inc Total Revenue for the quarter ending December 12, 2018 was $5,795m a 12.20% increase of 707m year over year
View Chart On Koyfin

Quarterly GILD Repurchase of Common Stock Data

09/2020$-201m
06/2020$-54m
03/2020$-1,328m
12/2019$-105m
09/2019$-222m
06/2019$-588m
03/2019$-834m
12/2018$-962m
09/2018$-449m
06/2018$-450m

Annual GILD Repurchase of Common Stock Data

2019$-1,749m
2018$-2,900m
2017$-954m
2016$-11,001m
2015$-10,002m
2014$-5,349m
2013$-582m
2012$-667m
2011$-2,383m
2010$-4,023m